Medical devices for the treatment of onychomycosis

Dermatologic Therapy

Volumn 25, Issue 6, 2012, Pages 574-581

  Gupta, Aditya K ^a,b   Simpson, Fiona C ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

iontophoresis; laser; onychomycosis; photodynamic therapy; ultrasound

Indexed keywords

AMINOLEVULINIC ACID; METHYL ESTER METHYLAMINOLEVULATE; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; TERBINAFINE; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ARTICLE; CELL DEATH; DIODE LASER; ECHOGRAPHY; FOLLOW UP; HUMAN; IONTOPHORESIS; LIGHT; LOW LEVEL LASER THERAPY; MEDICAL DEVICE; NEODYMIUM YAG LASER; ONYCHOMYCOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; SEMICONDUCTOR; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; HUMANS; IONTOPHORESIS; LASER THERAPY; ONYCHOMYCOSIS; PATIENT SATISFACTION; PHOTOCHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 84870575079     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01519.x     Document Type: Article

References (53)

1. de Berker DA, Andre J, Baran R,. Nail biology and nail science. Int J Cosmet Sci 2007: 29: 241-275. (Pubitemid 47101101)
2. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC,. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000: 43: 244-248. (Pubitemid 30626001)
3. Baran R,. The nail in the elderly. Clin Dermatol 2011: 29: 54-60.
4. Gupta AK, Humke S,. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000: 10: 379-384.
5. Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000: 14: 466-469. (Pubitemid 32899268)
6. Abdelaziz AM, Mahmoud KM, Elsawy EM, Bakr MA,. Nail changes in kidney transplant recipients. Nephrol Dial Transplant 2010: 25: 274-277.
7. Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000: 39: 746-753.
8. Döner N, Yaşar Ş, Ekmekçi TR,. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm 2011: 45: 146-151.
9. Baran R, Gupta AK, Piérard GE,. Pharmacotherapy of onychomycosis. Expert Opin Pharmacother 2005: 6: 609-624. (Pubitemid 40613888)
10. Kumar S, Kimball AB,. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs 2009: 18: 727-734.
11. Murdan S,. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008: 5: 1267-1282.
12. Murdan S,. 1st meeting on topical drug delivery to the nail. Expert Opin Drug Deliv 2007: 4: 453-455. (Pubitemid 47249142)
13. Piraccini BM, Sisti A, Tosti A,. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010: 62: 411-414.
14. Scher RK, Baran R,. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003: 149 (Suppl. 65): 5-9. (Pubitemid 37410064)
15. Shear N, Drake L, Gupta AK, Lambert J, Yaniv R,. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology 2000: 201: 196-203.
16. Anderson RR, Parrish JA,. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983: 220: 524-527. (Pubitemid 13114117)
17. Altshuler GB, Anderson RR, Manstein D, Zenzie HH, Smirnov MZ,. Extended theory of selective photothermolysis. Lasers Surg Med 2001: 29: 416-432. (Pubitemid 34016573)
18. FDA 510(k) Summary K093547. PinPointe FootLaser, PinPointe USA, Inc. 2010.
19. FDA 510(k) Summary K103626. Cutera GenesisPlus Laser System, Cutera, Inc. 2010.
20. FDA 510(k) Summary K110370. Q-Clear, Light Age, Inc. 2011.
21. FDA 510(k) Summary K103338. CoolTouch VARIA, New Star Lasers, Inc. 2011.
22. FDA 510(k) Summary K111483. Joule ClearSense, Sciton Inc. 2011.
23. Welch AJ, Torres JH, Cheong W,. Laser physics and laser-tissue interactions. Tex Heart Inst J 1989: 16: 141-149.
24. Patil UA, Dhami LD,. Overview of lasers. Indian J Plast Surg 2008: 41: S101-S113.
25. Kozarev J,. Summary: clearsteps-laser onychomycosis treatment: assessment of efficacy 12 months after treatment and beyond. J Laser Health Acad 2011: 2011: S07.
26. Kozarev J, Vizintin Z,. Novel laser therapy in treatment of onychomycosis. J Laser Health Acad 2010: 1: 1-8.
27. Harris DM, McDowell BA, Strisower J,. Laser treatment for toenail fungus. Proc. of SPIE. 2009; 7161: 71610M1-71610M7.
28. Weiss D,. 3 Month Clinical Results using Sub-millisecond 1064 nm Nd: YAG Laser for the Treatment of Onychomycosis. Weiss Foot and Ankle Center, Hammonton, NJ; 2011.
29. Hochman LG,. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011: 13 (1): 2-5.
30. Waibel J,. Introducing the Sciton ClearSense Accessory featuring the ClearToe treatment for Onychomycosis (For Non-U.S. Customers). Sciton Inc., Palo Alto, CA; 2012.
31. Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010: 100: 166-177.
32. Nomir Medical Technologies. Using light therapy to treat toe nail fungus. In: ClinicalTrials.gov editor: US NIH, 2008.
33. Nomir Medical Technologies. Treating onychomychosis. In: ClinicalTrials.gov editor: US NIH, 2008.
34. ConBio Inc. Diode Laser Treatment of Onychomycosis. http:// clinicaltrials.gov/ct2/show/NCT01452490. Accessed November 2012.
35. Smijs TG, van der Haas RN, Lugtenburg J, Liu Y, de, Jong RL, Schuitmaker HJ,. Photodynamic treatment of the dermatophyte Trichophyton rubrum and its microconidia with porphyrin photosensitizers. Photochem Photobiol 2004: 80: 197-202.
36. Smijs TG, Bouwstra JA, Talebi M, Pavel S,. Investigation of conditions involved in the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment. J Antimicrob Chemother 2007: 60: 750-759. (Pubitemid 47434252)
37. Smijs TG, Bouwstra JA, Schuitmaker HJ, Talebi M, Pavel S,. A novel ex vivo skin model to study the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment in different growth phases. J Antimicrob Chemother 2007: 59: 433-440. (Pubitemid 47073448)
38. Smijs TG, Mulder AA, Pavel S, Onderwater JJ, Koerten HK, Bouwstra JA,. Morphological changes of the dermatophyte Trichophyton rubrum after photodynamic treatment: a scanning electron microscopy study. Med Mycol 2008: 46: 315-325. (Pubitemid 351552486)
39. Smijs TG, Pavel S, Talebi M, Bouwstra JA,. Preclinical studies with 5,10,15-Tris(4-methylpyridinium)-20-phenyl-[21H,23H]-porphine trichloride for the photodynamic treatment of superficial mycoses caused by Trichophyton rubrum. Photochem Photobiol 2009: 85: 733-739.
40. Braathen LR, Szeimies R-M, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007: 56: 125-143. (Pubitemid 44969292)
41. Wiegell SR, Wulf HC, Szeimies RM, et al. Daylight photodynamic therapy for actinic keratosis: an international consensus. J Eur Acad Dermatol Venereol 2012: 26: 673-679.
42. Piraccini BM, Rech G, Tosti A,. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008: 59: S75-S76.
43. Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y,. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008: 144: 19-21. (Pubitemid 351159403)
44. Sotiriou E, Panagiotidou D, Ioannides D,. 5-Aminolevulininic acid photodynamic therapy treatment for tinea cruris caused by Trichophyton rubrum: report of 10 cases. J Eur Acad Dermatol Venereol 2009: 23: 341-342.
45. Gilaberte Y, Aspiroz C, Martes MP, Alcalde V, Espinel-Ingroff A, Rezusta A,. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol 2010: 65: 669-671.
46. Amichai B, Nitzan B, Mosckovitz R, Shemer A,. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2009: 162: 46-50.
47. Nair AB, Kim HD, Davis SP, et al. An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafine. Pharm Res 2009: 26: 2194-2201.
48. Nair AB, Kim HD, Chakraborty B, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009: 98: 4130-4140.
49. Nair AB, Vaka SR, Sammeta SM, et al. Trans-ungual iontophoretic delivery of terbinafine. J Pharm Sci 2009: 98: 1788-1796.
50. Nair AB, Sammeta SM, Kim HD, Chakraborty B, Friden PM, Murthy SN,. Alteration of the diffusional barrier property of the nail leads to greater terbinafine drug loading and permeation. Int J Pharm 2009: 375: 22-27.
51. Amichai B, Mosckovitz R, Trau H, et al. Iontophoretic terbinafine HCL 1.0% delivery across porcine and human nails. Mycopathologia 2010: 169: 343-349.
52. Nair AB, Vaka SR, Murthy SN,. Transungual delivery of terbinafine by iontophoresis in onychomycotic nails. Drug Dev Ind Pharm 2011: 37: 1253-1258.
53. Mididoddi P, Upadhye S, Church C, Davis S, Repka M,. Influence of etching and ultrasound on the permeability of ciclopirox through the human nail. American Association of Pharmaceutical Scientists Annual Meeting and Exposition. San Antonio, TX, 2006.